Neurocrine Biosciences (NASDAQ:NBIX) Shares Break Above 200-Day Moving Average After Insider Selling

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s share price crossed above its 200-day moving average during trading on Tuesday after an insider bought additional shares in the company. The stock has a 200-day moving average of $147.60 and traded as high as $169.53. Neurocrine Biosciences shares last traded at $164.85, with a volume of 4,056,875 shares traded.

Analysts Set New Price Targets

A number of research firms have commented on NBIX. Canaccord Genuity Group lifted their target price on Neurocrine Biosciences from $210.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup boosted their target price on Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday, October 16th. TD Cowen lifted their price target on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Royal Bank Of Canada boosted their price objective on shares of Neurocrine Biosciences from $187.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $201.55.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, exceeding estimates, while EPS of $3.29 also topped consensus. Product sales surpassed $1 billion for the first time. Neurocrine raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, citing demand across its portfolio. Third-quarter results
• Positive Sentiment: Several analysts raised price targets after the results: Canaccord to $220, Piper Sandler to $215, RBC to $190, and Morgan Stanley to $185. Ratings ranged from buy/outperform to equal weight, so the target increases were broadly supportive but not uniformly bullish.
• Positive Sentiment: The company said it has begun a Phase 2 Alzheimer’s study and plans to present its neuroscience work and pipeline at the NEI Fall Congress. These updates add to investor focus on longer-term development opportunities, though the supplied reports provide limited study details. Alzheimer’s study and education update
• Negative Sentiment: Director George J. Morrow reported sales totaling 15,000 shares across transactions on November 2–3, in addition to a 300-share sale on October 30. The filings say the transactions were made under a pre-arranged Rule 10b5-1 plan, which may temper concern, and he retained 10,386 shares.

Neurocrine Biosciences Price Performance

The firm’s 50-day moving average is $146.72 and its two-hundred day moving average is $147.60. The company has a market cap of $16.76 billion, a P/E ratio of 24.46, a PEG ratio of 0.64 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a return on equity of 24.11% and a net margin of 18.98%. The company’s quarterly revenue was up 41.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.04 earnings per share. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Ethic Inc. boosted its holdings in shares of Neurocrine Biosciences by 11.1% in the 3rd quarter. Ethic Inc. now owns 1,909 shares of the company’s stock valued at $271,000 after buying an additional 191 shares in the last quarter. Formidable Asset Management LLC bought a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $428,000. AlphaCentric Advisors LLC raised its stake in shares of Neurocrine Biosciences by 5.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 10,230 shares of the company’s stock worth $1,451,000 after acquiring an additional 503 shares in the last quarter. Parallel Advisors LLC lifted its position in Neurocrine Biosciences by 3.5% during the third quarter. Parallel Advisors LLC now owns 1,780 shares of the company’s stock valued at $252,000 after acquiring an additional 61 shares during the last quarter. Finally, Privium Fund Management B.V. purchased a new stake in Neurocrine Biosciences during the third quarter valued at approximately $3,716,000. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.